Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

Prime Medicine secures up to $24 million from the CF Foundation to advance Prime Editors for cystic fibrosis treatment. Prime Medicine, Inc. has announced an agreement with the Cystic Fibrosis ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the first-ever treatment built on CRISPR/Cas9 technology. That decision moved gene ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific presentations. PRME's Prime Editing platform targets multi-billion-dollar markets ...

Like base editing, prime editing offers a safer way to genome editing by relying on a nickase enzyme that “nicks” one DNA strand at a time, rather than cutting both simultaneously. Then, with the ...

Editor’s note: On June 3, 2025, KJ Muldoon was discharged from the hospital and is now at home with his family. When a baby born in Philadelphia was announced as the first person to get a gene therapy ...